CD274 and psoriasis: Anti-PDL1 treatments were associated with psoriasis and/or psoriatic arthritis development or exacerbation in a much smaller number of cases, most of which occurred during treatment with atezolizumab (eighteen cases of psoriasis), followed by durvalumab (twelve cases of psoriasis) and avelumab (one case of psoriasis).